Results 231 to 240 of about 72,525 (247)

Galangin increases the cytotoxic activity of imatinib mesylate in imatinib-sensitive and imatinib-resistant Bcr-Abl expressing leukemia cells

Cancer Letters, 2008
Rosaria Maria Pipitone, Manlio Tolomeo, Stefania Grimaudo   +2 more
exaly  

Imatinib

Reactions Weekly, 2017
openaire   +1 more source

A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study

Annals of Oncology, 2005
Steven Schild, G K Dy, A A Miller
exaly  

Participation of CYP2C8 and CYP3A4 in the N‐demethylation of imatinib in human hepatic microsomes

British Journal of Pharmacology, 2010
Michael Murray
exaly  

Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity

Annals of Oncology, 2008
Jourik Gietema, J A Gietema, W T A van der Graaf   +2 more
exaly  

Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL – Inhibition of P-glycoprotein function by 17-AAG

Leukemia, 2005
Stefan Fruehauf, Stephanie Laufs, J Topaly   +2 more
exaly  

Process of preparing imatinib and imatinib prepared thereby

2004
KANKAN RAJENDRA NARAYANRAO, RAO DHARMARAJ RAMACHANDRA   +1 more
openaire   +2 more sources

Determination of unbound fraction of imatinib and N-desmethyl imatinib, validation of an UPLC–MS/MS assay and ultrafiltration method

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012
Cecile Arellano, Peggy Gandia, Etienne Chatelut   +2 more
exaly  

Imatinib

Reactions Weekly, 2018
openaire   +2 more sources

Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients?

Annals of Oncology, 2010
Marco Fiore, Elena Tamborini, Alessandro Gronchi   +2 more
exaly